BioSpace News Archive

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. EST . The conference will be held in a virtual meeting format. Presentation details: Event: The JMP Securities Hematology Summit Date: Tuesday, Dec. 15 Time: 3:00 p.m. EST

Lilly Asia Ventures Fund and Arch Venture Partners co-lead $100M Series A financing to advance the establishment of a robust and innovative CNS pipeline

Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a fireside chat at the 2020 RBC Capital Markets Healthcare Private Company Conference on Tuesday, December 15, 2020 at 8:40 AM EST. About Axial Therapeutics Axial Therapeu

Company now has four CE marks in its portfolio for digital and computational pathology products Achievements build on company’s CE marks for first-in-class Paige Prostate Cancer Detection product and digital pathology viewer FullFocus TM in 2019

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that the first patient has been dosed in the Phase 2b SOOTHE trial of BLU-5937, the Company

Peijia Medical (HK Stock Code: 09996) successfully commenced the animal experiment for its mitral valve edge-to-edge repair product, advancing the development to the next stage. The commencement of this experiment reflects Peijia Medical’s long term commitment in developing independent intellectual property products. Rather than a “

Prelude Corporation (PreludeDx ™ ), a leader in molecular diagnostics and precision medicine for early stage breast cancer, will present clinical outcomes data on the company’s commercially available test, DCISi

Centene Corporation (NYSE: CNC) today announced that it has completed its acquisition of Apixio, a healthcare analytics company offering Artificial Intelligence (AI) technology solutions. With this transaction, Centene will continue to digitize the administration of healthcare and accelerate innovation and modernization across the enter

H3 Biomedicine, Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of three posters at the 2020 San Antonio Breast Cancer Symposium (SABCS). The presentations include interim data from H3’s ongoing Phase 1/2 clinical development program, H3B-6545, a potential first-in-class, orally available Selective ERα Covalent Antagonist (SERCA), in

Strong execution in Medical and Dental drives record financial results - Demand for infection prevention products continues to accelerate - Strong recurring revenue mix and cost discipline driving increased profitability - Hu-Friedy synergies well ahead of schedule - Net sales of $297.0M, up 15.5% - GAAP diluted EPS of $0.57, up 307.1% - Non-GAAP diluted EPS of $0.90, up 38.5% - GAAP net income of $24.5M, up 324.2%